Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
follitropin alfa Fc fusion protein
- Development stage
- Unknown
- Lead developer
- Guangzhou Youhuikang Biotechnology
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Follitropin alfa Fc fusion protein (UN008) is a long-acting recombinant human follicle-stimulating hormone (hFSH) Fc fusion protein developed by Guangzhou Unicohealth Biotechnology. The drug consists of a recombinant human FSH fused to a human IgG2 Fc variant (vIgG2Fc) via a peptide linker, structured with an hFSHβ subunit, CTP, an hFSHα subunit, a peptide linker, and the vIgG2Fc from N-terminal to C-terminal. By utilizing Unicohealth's proprietary γBloc Fc long-acting technology, the fusion protein achieves a significantly prolonged in vivo half-life (approximately 7 days) compared to conventional recombinant FSH, while avoiding potential ADCC/CDC side effects. It is designed to stimulate multifollicular development for assisted reproductive technology (ART) and controlled ovarian stimulation (COS) in women with female infertility and anovulation. The drug is currently in Phase I clinical development in China.
- Other names
- recombinant human follicle-stimulating hormone Fc fusion proteinhFSH-Fcrecombinant human FSH Fc fusion protein重组人促卵泡素Fc融合蛋白重组人促卵泡激素Fc融合蛋白
02
Targets
FSHR (Follicle-stimulating hormone receptor)FCGRT (Neonatal crystallizable fragment receptor)
Beyond the preview
Go deeper on follitropin alfa Fc fusion protein.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on follitropin alfa Fc fusion protein.